{"id":17235,"date":"2024-11-26T00:42:26","date_gmt":"2024-11-26T01:42:26","guid":{"rendered":"https:\/\/medexperts.pro\/?p=17235"},"modified":"2024-11-26T02:23:27","modified_gmt":"2024-11-26T02:23:27","slug":"trial-of-controversial-alzheimers-drug-halted-after-disappointing-results","status":"publish","type":"post","link":"https:\/\/medexperts.pro\/?p=17235","title":{"rendered":"Trial of Controversial Alzheimer\u2019s Drug Halted After Disappointing Results"},"content":{"rendered":"
<\/div>\n

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer\u2019s disease.<\/p>\n

\n
\n
\n

Cassava Sciences, a small biotechnology company based in Austin, Texas, announced it would stop the advanced clinical trial for an experimental Alzheimer\u2019s drug, ending a long-contested bid for regulatory approval.<\/p>\n

The company announced on Monday that the drug, simufilam, did not significantly reduce cognitive decline in people with mild to moderate Alzheimer\u2019s disease in the trial, which enrolled more than 1,900 patients.<\/p>\n

\u201cThe results are disappointing for patients and their families who are living with this disease and physicians who have been looking for novel treatment options,\u201d the company\u2019s chief executive, Richard J. Barry, said in a statement.<\/p>\n

These results were unsurprising to many dementia researchers, who had questioned why the trial had been allowed<\/a> to proceed in the first place, since much of the drug\u2019s underlying science had been called into question.<\/p>\n<\/div>\n<\/div>\n

<\/div>\n
\n
\n

Studies that once seemed to support the drug have been retracted from scientific journals. A consultant researcher who helped conduct some of the drug\u2019s foundational studies was charged<\/a> with fraud by a federal grand jury for allegedly falsifying data to obtain research grants.<\/p>\n

In September, the company settled<\/a> with the Securities and Exchange Commission over allegations that Cassava had made misleading statements about the results of earlier clinical trial data. However, the company neither admitted nor denied wrongdoing.<\/p>\n

Even so, the company forged ahead with its Phase 3 clinical trial \u2014 typically the last evaluation before the Food and Drug Administration decides whether to approve a medication for public use \u2014 and maintained that there was still research and clinical results that suggested the drug could prove valuable.<\/p>\n

Hopes in the drug\u2019s efficacy were dashed by Monday\u2019s results, though the company said the trial still showed the drug was safe.<\/p>\n

Cassava\u2019s future now appears to be in flux, as simufilam was the company\u2019s only drug in clinical trials.<\/p>\n<\/div>\n<\/div>\n

<\/div>\n
\n
\n

Following the company\u2019s investor call Monday morning, Cassava\u2019s stock price dropped more than 80 percent, a blow to the company\u2019s loyal investors, who once valued the company at more than $5 billion.<\/p>\n<\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer\u2019s disease.Cassava Sciences, a small biotechnology company based in Austin, Texas, announced it would stop the advanced clinical trial for an experimental Alzheimer\u2019s drug, ending a long-contested bid for regulatory approval.The company announced on Monday that the drug, simufilam, did not significantly reduce cognitive decline in people with mild to moderate Alzheimer\u2019s disease in the trial, which enrolled more than 1,900 patients.\u201cThe results are disappointing for patients and their families who are living with this disease and physicians who have been looking for novel treatment options,\u201d the company\u2019s chief executive, Richard J. Barry, said in a statement.These results were unsurprising to many dementia researchers, who had questioned why the trial had been allowed to proceed in the first place, since much of the drug\u2019s underlying science had been called into question.Studies that once seemed to support the drug have been retracted from scientific journals. A consultant researcher who helped conduct some of the drug\u2019s foundational studies was charged with fraud by a federal grand jury for allegedly falsifying data to obtain research grants.In September, the company settled with the Securities and Exchange Commission over allegations that Cassava had made misleading statements about the results of earlier clinical trial data. However, the company neither admitted nor denied wrongdoing.Even so, the company forged ahead with its Phase 3 clinical trial \u2014 typically the last evaluation before the Food and Drug Administration decides whether to approve a medication for public use \u2014 and maintained that there was still research and clinical results that suggested the drug could prove valuable.Hopes in the drug\u2019s efficacy were dashed by Monday\u2019s results, though the company said the trial still showed the drug was safe.Cassava\u2019s future now appears to be in flux, as simufilam was the company\u2019s only drug in clinical trials.Following the company\u2019s investor call Monday morning, Cassava\u2019s stock price dropped more than 80 percent, a blow to the company\u2019s loyal investors, who once valued the company at more than $5 billion.<\/p>\n","protected":false},"author":1,"featured_media":17237,"comment_status":"close","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[],"class_list":["post-17235","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-science"],"_links":{"self":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/17235","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17235"}],"version-history":[{"count":2,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/17235\/revisions"}],"predecessor-version":[{"id":17238,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/17235\/revisions\/17238"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/media\/17237"}],"wp:attachment":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17235"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=17235"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=17235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}